Vedolizumab Therapy in Refractory Enteropathy Associated With CVID

Area of Science:

• Immunology
• Gastroenterology

Background:

• Common variable immunodeficiency (CVID) is characterized by hypogammaglobulinemia and increased susceptibility to infections.
• Noninfectious gastrointestinal manifestations, including severe enteropathy, are increasingly recognized in CVID patients.
• Severe enteropathy in CVID can lead to malabsorption, weight loss, and debilitating diarrhea.

Observation:

• A 63-year-old male patient with CVID presented with severe enteropathy.
• The patient's condition was refractory to conventional treatments, including empiric therapies, cytomegalovirus treatment, and corticosteroids.
• Vedolizumab, a biologic agent targeting the gut, was administered.

Findings:

• Vedolizumab treatment resulted in a dramatic and rapid clinical improvement.
• The patient experienced a durable complete response, with resolution of enteropathy symptoms.
• This indicates a significant therapeutic benefit of vedolizumab in this challenging clinical scenario.

Implications:

• Vedolizumab may represent a novel and effective therapeutic option for severe enteropathy in CVID.
• Targeting gut inflammation with vedolizumab could be a viable strategy for managing refractory gastrointestinal complications in immunodeficiency disorders.
• Further research is warranted to explore the efficacy and safety of vedolizumab in a broader CVID population with gastrointestinal involvement.